12 |
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial
|
2022-06-28 |
3 |
11 |
Survival with Cemiplimab in Recurrent Cervical Cancer
|
2022-03-31 |
33 |
10 |
Association of Germiline BRCA Pathogenic Variants With Diminished Ovarian Reserve: A Meta-Analysis of Individual Patient-Level Data
|
2022-03-30 |
21 |
9 |
SUCCOR cone study: conization before radical hysterectomy
|
2022-02-14 |
28 |
8 |
Randomized Trial of Cytoreductive Surgery for Relapsed Ovarian Cancer
|
2021-12-20 |
18 |
7 |
Maintenance olaparib for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation (SOLO1/GOG 3004): 5-year follow-up of a randomised, double-blind, placebo-controlled, phase 3 trial
|
2021-12-20 |
14 |
6 |
Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers
|
2021-08-19 |
24 |
5 |
Long-Term Risk of Ovarian Cancer and Borderline Tumors After Assisted Reproductive Technology
|
2021-08-19 |
32 |
4 |
Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study
|
2021-08-02 |
22 |
3 |
Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial
|
2021-04-27 |
52 |